Skip to main content
. 2024 May 30;34(7):1433–1442. doi: 10.4014/jmb.2401.01027

Fig. 4. miR-302e targets MBNL3 to modulate GAC progression.

Fig. 4

(A) The miRNAs (miR-302e, miR-130a-3p, miR- 301a-3p, miR-130b-3, miR-301b-3p and miR-454-3p) that can combine with MBNL3 were confirmed through intersecting "TargetScan," "starbase," "miRDB," and "tarbase" online databases. (B) The MBNL3 mRNA expression was examined after overexpressing these miRNAs (miR-302e, miR-130a-3p, miR-301a-3p, miR-130b-3, miR-301b-3p and miR-454-3p). **p < 0.01, ***p < 0.001. (C) The MBNL3 protein expression was determined after overexpressing miR-302e. ***p < 0.001. (D) The miR-302e expression was tested through RT-q PCR. ***p < 0.001. (E) The binding sites (WT or MUT) of MBNL3 for miR- 302e and were shown. (F) The binding abilities among miR-302e and MBNL3 were assessed through luciferase reporter assay. ***p < 0.001. (G) The cell proliferation was evaluated through CCK-8 assay. (H) The cell invasion was examined through Transwell assay. (I) The angiogenic ability was evaluated through tube formation assay. Groups were separated into the NC mimic, miR-302e mimic and miR-302e mimic+MBNL3 group. ***p < 0.001 vs the NC mimic group; ###p < 0.001 vs. the miR- 302e mimic group.